ERB-Modified Fluoroquinolones: Antibacterial Activity and PK/PD Profiles

Mark Laws reports a dataset on novel Efflux Resistance Breaker (ERB)-modified fluoroquinolone antibiotics. The data includes antibacterial activity metrics, such as MIC reductions up to 512-fold and IC50 values for DNA gyrase inhibition, alongside pharmacokinetic/pharmacodynamic profiles from a murine infection model. The dataset was last updated on 2026-05-29.

Use Cases

• Modeling structure-activity relationships for ERB-modified fluoroquinolones based on reported MIC and IC50 values.
• Training predictive models for oral bioavailability using the reported favorable PK/PD profiles.
• Benchmarking new compounds against lead molecules KSN-L22 and BL-7 based on their activity against multidrug-resistant pathogens.
• Analyzing toxicity and off-target profiles based on the reported absence of hERG, CYP450, or other liabilities.

Strengths

• Includes specific potency metrics, such as a 512-fold reduction in MIC and an IC50 of ~3.8 μg/mL for DNA gyrase inhibition.
• Reports in vivo efficacy data, showing a >4-log bacterial load reduction in a murine thigh infection model.
• Contains detailed safety and pharmacokinetic data, including absence of toxicity at 1200 mg/kg/day and favorable oral/IV profiles.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small (459.2 KB), indicating a limited scope of data points.

Provenance

Source

Mark Laws via figshare

Collection Method

Likely contains experimental results from antibiotic design and testing.

Freshness

Last updated 2026-05-29 04:48:38; freshness should be verified.